Issue Code: PHA
1,778
457
277
2025--2026
LMH STRATEGIC SOLUTIONS
62 activities
MARSHALL & POPP, LLC
49 activities
MEHLMAN CONSULTING, INC.
46 activities
TODD STRATEGY GROUP
HOUSE OF REPRESENTATIVES
1,428 mentionsSENATE
1,411 mentionsHealth & Human Services, Dept of (HHS)
381 mentionsCenters For Medicare and Medicaid Services (CMS)
AMGEN
via PANNONE LOPES DEVEREAUX & O'GARA LLC
Prescription drug pricing.
ADNEURIS THERAPEUTICS, INC.
via MAD GLOBAL STRATEGY
Education on new drug seeking FDA approval
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
via BGR GOVERNMENT AFFAIRS
8 activities
41 activities
B HALL STRATEGIES, LLC
39 activities
RUBICON ADVISORS, LLC
37 activities
BALLARD PARTNERS
34 activities
DLA PIPER LLP (US)
32 activities
BGR GOVERNMENT AFFAIRS
30 activities
BUCHANAN INGERSOLL & ROONEY PC
28 activities
Food & Drug Administration (FDA)
182 mentionsWhite House Office
151 mentionsExecutive Office of the President (EOP)
107 mentionsOffice of Management & Budget (OMB)
36 mentionsHealth Resources & Services Administration (HRSA)
36 mentionsCommerce, Dept of (DOC)
30 mentionsProvide strategic counsel and advocate on issues related to health care legislative and regulatory issues.
IQVIA
via REPUBLIC CONSULTING, LLC
monitor health data policy.
ALLERGY & ASTHMA NETWORK
via ALLERGY & ASTHMA NETWORK
Healthcare, drug pricing, insurance, affordability, access to treatment, Medicare, Medicaid, Affordable Care Act, environmental protections, clean air, clean water, emergency preparedness, epinephrine, airline allergy safety, and air quality.
ADNEURIS THERAPEUTICS, INC.
via MAD GLOBAL STRATEGY
FDA approval of new drug
SENTRY DATA SYSTEMS
via THE OUTLAW GROUP
Issues impacting the 340B program
KNOA PHARMA LLC
via MERCURY PUBLIC AFFAIRS, LLC
Affordable access to overdose reversal medications and support opioid abatement programs
CURIUM
via CAPITOL COUNSEL LLC
Issues regarding radiopharmaceutical New Drug Application (NDA) approvals.
DJP SOVEREIGNTY ADVISORS
via DJP SOVEREIGNTY ADVISORS
Proposals, amendments, and federal initiatives relating to domestic manufacturing, supply chain resiliency, and technological sovereignty under the CHIPS and Science Act framework. Executive branch and legislative actions concerning federal tax credits, domestic sourcing, and Foreign Entity of Concern (FEOC) compliance mitigation. Specific provisions related to the STRIDE Act (CHIPS 2.0), regarding National Thermal Shield Deployment, advanced technology supply chain corridors, and FEOC mitigation strategies utilizing international trade manufacturing stacks. Public policy and regulatory frameworks impacting healthcare delivery networks, pharmaceutical development, biotechnology, and corporate financial compliance.